Systemic lupus erythematosus (SLE) is an autoimmune disease marked by the disruption of the immune homeostasis. Patients exhibit a wide range of clinical manifestations, and environmental and genetic factors are involved in SLE pathogenesis. Evidence suggests that abnormalities in the cellular and molecular events that coordinate apoptosis may favour the generation of autoantigens involved in autoimmunity. In this way, the apoptotic deregulation may be affected by polymorphic variants in apoptotic-related genes.
Methods
We analyzed FAS, FASL, BCL-2 and BAX polymorphisms in order to correlate to SLE susceptibility and clinical features. A total of 427 SLE patients from the Hospital de Clínicas de Porto Alegre and 543 controls from southern Brazil were evaluated.
Results
We observed higher frequencies of the FASL –844CC genotype and –844C allele, as well as of the FASL-844C/IVS2nt-124A haplotype in African-derived SLE patients when compared to controls (P < 0.001). FASL –844C, which is related to high FasL expression, could contribute to increased apoptosis and to the breakdown of immunological tolerance, favouring autoantibody production and inflammation. On the other hand, the BAX –248GA genotype and the –248A allele, related to low protein expression, were observed as a protective factor against SLE in this same population. The rate of apoptosis and cell death was evaluated in peripheral lymphocytes, and SLE patients presented a higher percentage of dead lymphocytes (CD3+Annexin V+ 7-AAD+) compared to the control group.
Conclusion
Our data support a role for apoptosis in SLE susceptibility.
CrispinJCLiossisSNKis-TothK. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med2010; 16(2): 47–57.
2.
MoudiBSalimiSFarajian MashhadiF. Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. Scientific World Journal2013; 2013: 176741–176741.
3.
RekvigOPVan der VlagJ. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol2014; 36(3): 301–311.
4.
MolokhiaMMcKeigueP. Systemic lupus erythematosus: genes versus environment in high risk populations. Lupus2006; 15(11): 827–832.
5.
XueCLan-LanWBeiC. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cellular Immunol2006; 239(2): 121–128.
6.
KaplanMJ. Apoptosis in systemic lupus erythematosus. Clin Immunol2004; 112(3): 210–218.
7.
PieterseEvan der VlagJ. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol2014; 5: 164–164.
8.
MonticieloOAMucenicTXavierRM. The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol2008; 27(4): 413–419.
9.
ZhuoWZhangYXiangZ. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12,226 cases and 10,782 controls. J Exp Clin Cancer Res2009; 28: 115–115.
10.
ChenKHuZWangLE. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis2007; 28(9): 2008–2012.
11.
NagyGKonczAPerlA. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol2005; 25(2): 123–140.
12.
FengY. [Studies on Fas ligand expression in patients with systemic lupus erythematosus]. Hokkaido Igaku Zasshi1997; 72(4): 443–455.
13.
NolsoeRLKellyJAPociotF. Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia. Genes Immun2005; 6(8): 699–706.
14.
NagataSSudaT. Fas and Fas ligand: lpr and gld mutations. Immunology Today1995; 16(1): 39–43.
15.
LeeYHKimYRJiJD. Fas promoter –670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol2001; 28(9): 2008–2011.
16.
Mohammadzadeh A, Pourfathollah AA, Tahoori MT, et al. Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients. Rheumatol Int 2011; 32(9): 2833–2836.
17.
BornerC. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol2003; 39(11): 615–647.
18.
BrownR. The bcl-2 family of proteins. Br Med Bull1997; 53(3): 466–477.
19.
LiphausBLKissMH. The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics (Sao Paulo)2010; 65(3): 327–333.
KohlerKFPetzl-ErlerML. No evidence for association of the TP53 12139 and the BAX-248 polymorphisms with endemic pemphigus foliaceus (fogo selvagem). Int J Immunogenet2006; 33(2): 141–144.
22.
LiCPLiJHHeSY. Roles of Fas/Fasl, Bcl-2/Bax, and Caspase-8 in rat nonalcoholic fatty liver disease pathogenesis. Genet Mol Res2014; 13(2): 3991–3999.
23.
HuangQRDanisVLassereM. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology1999; 38(7): 645–651.
24.
HuangQRManoliosN. Investigation of the –1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology2000; 32(2): 126–130.
25.
VeitTDCorderoEAMucenicT. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus2009; 18(5): 424–430.
26.
VargasAEMarreroARSalzanoFM. Frequency of CCR5delta32 in Brazilian populations. Braz J Med Biol Res2006; 39(3): 321–325.
27.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40(9): 1725–1725.
28.
VitaliCBombardieriSJonssonR. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis2002; 61(6): 554–558.
29.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: JTH2006; 4(2): 295–306.
30.
GladmanDGinzlerEGoldsmithC. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39(3): 363–369.
31.
BombardierCGladmanDDUrowitzMB. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35(6): 630–640.
32.
LahiriDKNurnbergerJIJr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acids Res1991; 19(19): 5444–5444.
33.
SunTMiaoXZhangX. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst2004; 96(13): 1030–1036.
34.
ZhangZWangLESturgisEM. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res2006; 12(18): 5596–5602.
35.
ZhangNLiXTaoK. BCL-2 (–938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet2011; 12: 48–48.
36.
MoshynskaOSankaranKSaxenaA. Molecular detection of the G(–248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. Mol Pathol2003; 56(4): 205–209.
37.
LongJCWilliamsRCUrbanekM. An E–M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet1995; 56(3): 799–810.
38.
WuJMetzCXuX. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol2003; 170(1): 132–138.
39.
XiangNLiXMWangGS. Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep2013; 40(1): 407–415.
40.
Pons-EstelGJAlarconGSScofieldL. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum2010; 39(4): 257–268.
41.
ChenJYWangCMMaCC. The –844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE. Genes Immun2005; 6(2): 123–128.
42.
LuMMYeQLFengCC. Association of FAS gene polymorphisms with systemic lupus erythematosus: a case–control study and meta-analysis. Exp Ther Med2012; 4(3): 497–502.
43.
SantosNPRibeiro-RodriguesEMRibeiro-Dos-SantosAK. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat2010; 31(2): 184–190.
44.
WangMWuDTanM. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet2009; 47(7–8): 559–568.
45.
OhsakoSHaraMHarigaiM. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol1994; 73(1): 109–114.
46.
JohanssonCCastillejo-LopezCJohannesonB. Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families. Genes Immun2000; 1(6): 380–385.
47.
OcanaMGValle-GarayEMontesAH. Bax gene G(–248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genet Med2007; 9(4): 249–255.
48.
SaxenaAMoshynskaOSankaranK. Association of a novel single nucleotide polymorphism, G(–248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett2002; 187(1–2): 199–205.
49.
FeganCStarczynskiJPrattG. The role of the bax gene polymorphism G(–248)A in chronic lymphocytic leukemia. Leukemia2006; 20(8): 1460–1461.
50.
CaricchioRCohenPL. Spontaneous and induced apoptosis in systemic lupus erythematosus: multiple assays fail to reveal consistent abnormalities. Cell Immunol1999; 198(1): 54–60.
